A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions

Covid19

Interventions

DRUG

ADX-629

ADX-629 administered orally twice daily (BID) for up to 28 days.

DRUG

Placebo

Placebo administered orally BID for up to 28 days.

Trial Locations (1)

Medical Research Center of Miami II, Inc., Miami